CCIA
FATE icon

Campbell & Co Investment Adviser’s Fate Therapeutics FATE Stock Holding History

Campbell & Co Investment Adviser’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-324,585
Closed -$1.06M – 1164
2024
Q2 		$1.06M Buy
+324,585
New +$1.42M 0.09% 340
2023
Q2 		– Sell
-59,651
Closed -$340K – 961
2023
Q1 		$340K Buy
59,651
+9,929
+20% +$59.9K 0.06% 564
2022
Q4 		$502K Buy
49,722
+35,290
+245% +$663K 0.12% 313
2022
Q3 		$323K Buy
+14,432
New +$417K 0.07% 457

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return

Campbell & Co Investment Adviser's FATE Position: Q3 2024 in Review

Campbell & Co Investment Adviser sold out of Fate Therapeutics (FATE) in Q3 2024, closing a stake of 324,585 shares — an estimated $1.06M sold.

Campbell & Co Investment Adviser first reported a position in FATE in Q3 2022 and held it in 4 quarters. The position peaked at $1.06M in Q2 2024. 164 funds tracked by Wall St. Rank hold FATE as of Q3 2024.

  • Campbell & Co Investment Adviser reported no remaining Fate Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Campbell & Co Investment Adviser sold 324,585 Fate Therapeutics shares in Q3 2024, an estimated $1.06M.
  • Campbell & Co Investment Adviser first reported a position in Fate Therapeutics in Q3 2022 and held it in 4 quarters.
  • Campbell & Co Investment Adviser's Fate Therapeutics position peaked at $1.06M in Q2 2024.
  • 164 funds tracked by Wall St. Rank held Fate Therapeutics as of Q3 2024.

Based on Campbell & Co Investment Adviser's 13F filing for Q3 2024, filed 12 Nov 2024.